Ionis Pharmaceuticals announced positive results from two pivotal Phase 3 trials demonstrating that olezarsen markedly reduced fasting triglycerides by up to 72% and decreased acute pancreatitis events by 85% in patients with severe hypertriglyceridemia. The therapy showed favorable safety and tolerability profiles, primarily mild injection site reactions. These data support expanding olezarsen’s label and position it for a larger market targeting severe triglyceride-related diseases.